8 April 2022

The Mycobacterial Cohort Study (MyCoS) stores biomaterial (plasma, serum, PBMC’s, PAXgene and DNA) from patients being treated at Radboudumc for a mycobacterial infection, together with data about the patient's disease course. Through the MyCoS biobank a platform will be created to answer diagnostic, pathophysiological and prognostic questions about mycobacterial infections.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl)

19 July 2022

The Ministry of Health, Welfare and Sport (VWS) is currently preparing a Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl) which will serve in the future as a specific legal framework for the (further) use of body tissue for medical scientific research.

read more

Health-RI annual report

19 July 2022

Health-RI has presented the 2021 annual report. In this report they outline an overview of recent activities and results of the past year 2021 (in Dutch).

read more

SPIDI sub-biobank

19 July 2022

The SPIDI collection aims to assess the prognostic value of MRI-DWI (new form of MRI research) and biomarkers (brain-specific proteins in cerebrospinal fluid) in the first 24 hours after the occurrence of a spinal cord injury as a result of trauma.

read more

Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021 The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands. read more